26 January 2022
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing
Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Non-Executive Chairman Matthew Wakefield and Chief Financial Officer, Paul Stockdale, have purchased Ordinary Shares of 1 pence each ("shares") as follows:
| Name | Number of shares purchased | Average price per share |
| Matthew Wakefield | 75,000 | 28.6p |
| Paul Stockdale | 35,000 | 27.2p |
Following these transactions, Matthew Wakefield and Paul Stockdale are respectively interested in the Ordinary Shares of the Company as follows:
| Name | Number of Ordinary shares held | % of issued share capital |
| Matthew Wakefield | 575,000 | 0.57 |
| Paul Stockdale | 70,000 | 0.07 |
The notifications below, made in accordance with the requirements of UK Market Abuse Regulation, provide further details:
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a) | Name | Matthew Wakefield | ||||||
| 2 | Reason for the notification | |||||||
| a) | Position/status | Director/PDMR | ||||||
| b) | Initial notification/ Amendment | Initial notification | ||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name | Oxford BioDynamics Plc | ||||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 | ||||||
| b) | Nature of the transaction | Acquisition of ordinary shares | ||||||
| c) | Price(s) and volume(s) |
| ||||||
| d) | Aggregated information - Aggregated volume - Price
|
| ||||||
| e) | Dates of the transactions | 25 January 2022 | ||||||
| f) | Place of the transaction | London Stock Exchange (XLON) | ||||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | Paul Stockdale | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Director/PDMR | ||||
| b) | Initial notification/ Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Oxford BioDynamics Plc | ||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 | ||||
| b) | Nature of the transaction | Acquisition of ordinary shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price
|
| ||||
| e) | Dates of the transactions | 26 January 2022 | ||||
| f) | Place of the transaction | London Stock Exchange (XLON) | ||||
For more information:
| Oxford BioDynamics Plc | Tel: +44 (0)1865 518910 |
| Jon Burrows, CEO Paul Stockdale, CFO |
|
|
|
|
| Shore Capital - Nominated Adviser and Broker | Tel: +44 (0)20 7408 4090 |
| Advisory: Stephane Auton / John More Broking: Fiona Conroy |
|
|
|
|
| Instinctif Partners - Financial PR | Tel: +44 (0)20 7457 2020 |
| Melanie Toyne-Sewell / Nathan Billis | OxfordBioDynamics@instinctif.com |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit. Its next product will be EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, to be launched in 2022.
The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow on Twitter or LinkedIn.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
